financetom
Business
financetom
/
Business
/
US to axe Biden-era 7-year deadline on exports from new LNG projects
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US to axe Biden-era 7-year deadline on exports from new LNG projects
Apr 1, 2025 1:41 PM

WASHINGTON/Houston, April 1 (Reuters) - The U.S. is

slated on Wednesday to rescind a policy issued by the

administration of former President Joe Biden that requires

liquefied natural gas, or LNG, projects to export within seven

years of receiving regulatory approval.

The LNG industry had pushed the administration of President

Donald Trump to rescind the policy statement issued in April

2023 on Department of Energy approvals for exports to big

markets in Europe and Asia because several projects require more

than seven years to complete.

"Henceforth, DOE will consider applications to extend an

authorization holder's export commencement deadline and grant

such extensions for good cause shown on a case-by-case basis, an

approach consistent with DOE's practice prior to the issuance of

the Policy Statement," said a document slated to be published in

the Federal Register on Wednesday.

Tala Goudarzi, principal deputy assistant secretary of the

Office of Fossil Energy and Carbon Management, said the Biden

administration had made it unnecessarily difficult for projects

to obtain and maintain an authorization to export LNG to

non-free-trade-agreement countries.

Pipeline operator Energy Transfer ( ET ) in 2023 filed for a

new export license for its proposed 16.45 million metric tons

per annum Lake Charles LNG facility in Louisiana, after the DOE

denied its request for a three-year extension to its old one,

saying it did not meet the criteria.

Energy Transfer ( ET ) was not immediately available for

comment.

Fred Hutchison, president and CEO of LNG Allies, a trade

group, called the previous deadline policy inflexible and said

the new policy marked a return to regular order.

"We are grateful that a commonsense approach has returned to

the U.S. LNG export process," Hutchison said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Factbox-US, Canadian companies kick off 2024 with layoffs
Factbox-US, Canadian companies kick off 2024 with layoffs
Apr 3, 2024
(Reuters) -Companies in the United States and Canada have kicked off 2024 with thousands of job cuts across sectors, signaling that the spate of layoffs seen in 2023 could persist as they scramble to rein in costs. While hopes of a soft landing have grown in recent months, companies continue to be cautious as the outlook on rate cuts by...
Asensus Surgical Shares Soar After KARL STORZ Acquisition Offer Announcement
Asensus Surgical Shares Soar After KARL STORZ Acquisition Offer Announcement
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Asensus Surgical ( ASXC ) shares jumped more than 28% in recent trading after the company said Wednesday that it has entered into a non-binding letter of intent with medical technology company KARL STORZ for a potential acquisition of Asensus. Asensus said that the letter of intent includes the proposal to acquire all...
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Alto Neuroscience ( ANRO ) said Wednesday it has started a phase 2 study of ALTO-203 in major depressive disorder patients. Alto said it expects to enroll about 60 adult participants with MDD and anhedonia, with top-line data expected in H1 of 2025. The company said ALTO-203 showed a favorable tolerability profile across...
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Merck ( MRK ) and Daiichi Sankyo said Wednesday they have dosed the first patient in a phase 2/3 trial assessing the efficacy and safety of investigational drug raludotatug deruxtecan to potentially treat ovarian cancer resistant to platinum-based chemotherapy. The second phase of the study is being done to establish the dose of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved